Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
University of Utah Health Sciences Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
University of Colorado
mi
from
Aurora, CO
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
Northwestern University
mi
from
Chicago, IL
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
The Mayo Clinic
mi
from
Rochester, MN
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
Respiratory Specialists
mi
from
Wyomissing, PA
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
Respiratory Specialists
mi
from
Wyomissing, PA
Click here to add this to my saved trials
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated:  12/8/2017
University of Calgary
mi
from
Calgary,
Simvastatin Therapy for Moderate and Severe COPD
Prospective Randomized Placebo-Controlled Trial of SimvaSTATin in the Prevention of COPD Exacerbations (STATCOPE)
Status: Enrolling
Updated: 12/8/2017
University of Calgary
mi
from
Calgary,
Click here to add this to my saved trials
Flunisolide HFA in Children With Small Airway Disease
Flunisolide HFA in Children With Small Airway Disease
Status: Enrolling
Updated:  12/13/2017
University of Louisville Pediatric Pulmonology
mi
from
Louisville, KY
Flunisolide HFA in Children With Small Airway Disease
Flunisolide HFA in Children With Small Airway Disease
Status: Enrolling
Updated: 12/13/2017
University of Louisville Pediatric Pulmonology
mi
from
Louisville, KY
Click here to add this to my saved trials
Mindfulness to Mitigate the Effect of Anxiety-depression-fear in Chronic Obstructive Pulmonary Disease (COPD)
Mindfulness to Mitigate the Effect of Anxiety-depression-fear in COPD
Status: Enrolling
Updated:  12/20/2017
The Mayo Clinic
mi
from
Rochester, MN
Mindfulness to Mitigate the Effect of Anxiety-depression-fear in Chronic Obstructive Pulmonary Disease (COPD)
Mindfulness to Mitigate the Effect of Anxiety-depression-fear in COPD
Status: Enrolling
Updated: 12/20/2017
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function
Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function
Status: Enrolling
Updated:  12/21/2017
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
mi
from
New York, NY
Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function
Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function
Status: Enrolling
Updated: 12/21/2017
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated:  12/23/2017
Jefferson County
mi
from
Louisville, KY
Asthma Data Innovation Demonstration Project
Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management
Status: Enrolling
Updated: 12/23/2017
Jefferson County
mi
from
Louisville, KY
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
UAB Lung Health Center
mi
from
Birmingham, AL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
UAB Lung Health Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Vapahcs 111P
mi
from
Palo Alto, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Vapahcs 111P
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
GLAHS Sepulveda
mi
from
Sepulveda, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
GLAHS Sepulveda
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Rehabilitation Clinical Trial Center
mi
from
Torrance, CA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Rehabilitation Clinical Trial Center
mi
from
Torrance, CA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Hospital for Special Care
mi
from
New Britain, CT
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Hospital for Special Care
mi
from
New Britain, CT
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Bay Pines Va Medical Center
mi
from
Bay Pines, FL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Bay Pines Va Medical Center
mi
from
Bay Pines, FL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
205.452.01195 Boehringer Ingelheim Investigational Site
mi
from
Panama City, FL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1218.64.10018 Boehringer Ingelheim Investigational Site
mi
from
Pembroke Pines, FL
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1218.64.10018 Boehringer Ingelheim Investigational Site
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
LSUHSC Shreveport
mi
from
Shreveport, LA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
LSUHSC Shreveport
mi
from
Shreveport, LA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
VAMC-Reno
mi
from
Reno, NV
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
VAMC-Reno
mi
from
Reno, NV
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
North Shore Universtiy Hospital
mi
from
New Hyde Park, NY
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
North Shore Universtiy Hospital
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
SVMMC
mi
from
Toledo, OH
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
SVMMC
mi
from
Toledo, OH
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1245.28.10020 Boehringer Ingelheim Investigational Site
mi
from
Medford, OR
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Hershey Medical Center
mi
from
Hershey, PA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Frank Sciurba
mi
from
Pittsburgh, PA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Frank Sciurba
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
MUSC
mi
from
Charleston, SC
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Harker Heights, TX
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Harker Heights, TX
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Medvamc
mi
from
Houston, TX
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Medvamc
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
McGuire VA
mi
from
Fredericksburg, VA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
McGuire VA
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Click here to add this to my saved trials
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated:  12/27/2017
CHU du Sart Tilman (B35)
mi
from
Angleur,
Dose Finding Study in COPD
A Randomized, Multiple-dose, Double-blind, Placebo- and Active-controlled, Parallel Group Efficacy and Safety Study to Determine the Optimum Dose of BEA 2180 BR Delivered by the Respimat® Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Status: Enrolling
Updated: 12/27/2017
CHU du Sart Tilman (B35)
mi
from
Angleur,
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
1301.1.5553 Boehringer Ingelheim Investigational Site
mi
from
Lakewood, CA
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
1301.1.5553 Boehringer Ingelheim Investigational Site
mi
from
Lakewood, CA
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
205.346.108 Boehringer Ingelheim Investigational Site
mi
from
Sepulveda, CA
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
205.346.108 Boehringer Ingelheim Investigational Site
mi
from
Sepulveda, CA
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
205.440.1002 Boehringer Ingelheim Investigational Site
mi
from
Torrance, CA
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
205.440.1002 Boehringer Ingelheim Investigational Site
mi
from
Torrance, CA
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
1222.29.11012 Boehringer Ingelheim Investigational Site
mi
from
Wheat Ridge, CO
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
205.452.01059 Boehringer Ingelheim Investigational Site
mi
from
Coeur D'Alene, ID
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
205.452.01091 Boehringer Ingelheim Investigational Site
mi
from
Shreveport, LA
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
205.452.01091 Boehringer Ingelheim Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated:  12/27/2017
205.346.510
mi
from
Bs As,
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Status: Enrolling
Updated: 12/27/2017
205.346.510
mi
from
Bs As,
Click here to add this to my saved trials